All In Biotech

Drug Trial Radar · NCT00232180

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure

Last checked: Nov 20, 2026Latest source record: Dec 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,743

Actual

Start

Mar 2006

Primary completion

May 2010

Study completion Jan 2012

Sponsor

Sponsor type
Industry
First posted
Oct 4, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus standard heart failure medicines is being compared to placebo plus standard heart failure medicines in terms of an additional ability to prolong life and prevent re-hospitalizations for worsening heart failure in these patients. The Data Safety Monitoring Committee (DSMC) observed during its conduct of the protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of eplerenone had met the pre-specified stopping rules in the protocol. As a result of the discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration that it would be unethical not to offer this treatment to patients, the ESC recommended that all the patients in the trial should be transferred to open-label eplerenone. The Open Label Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for the indication studied in this patient population. On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered to be the most appropriate way to ensure that all the subjects who participated in the double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone

Conditions

  • Heart Failure

Interventions

  • EplerenoneDrug

    Eplerenone administered on top of background standard heart failure therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off DateTime frame: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
  2. Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated)Time frame: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)

Locations

307 sites in 29 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Loma Linda, California

  • Pfizer Investigational Site

    Merced, California

  • Pfizer Investigational Site

    Stockton, California

  • Pfizer Investigational Site

    Colorado Springs, Colorado

  • Pfizer Investigational Site

    Bridgeport, Connecticut

  • Pfizer Investigational Site

    Hartford, Connecticut

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Daytona Beach, Florida

  • Pfizer Investigational Site

    Gainesville, Florida

  • Pfizer Investigational Site

    Jupiter, Florida

  • Pfizer Investigational Site

    Melbourne, Florida

  • Pfizer Investigational Site

    Rockford, Illinois

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Baton Rouge, Louisiana

  • Pfizer Investigational Site

    Bangor, Maine

  • Pfizer Investigational Site

    Annapolis, Maryland

  • Pfizer Investigational Site

    Columbia, Maryland

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Minneapolis, Minnesota

  • Pfizer Investigational Site

    MN, Minnesota

  • Pfizer Investigational Site

    Tupelo, Mississippi

  • Pfizer Investigational Site

    Tupelo, Mississippi

  • Pfizer Investigational Site

    Omaha, Nebraska

  • Pfizer Investigational Site

    Omaha, Nebraska

  • Pfizer Investigational Site

    Omaha, Nebraska

  • Pfizer Investigational Site

    Manchester, New Hampshire

  • Pfizer Investigational Site

    Albany, New York

  • Pfizer Investigational Site

    Rochester, New York

  • Pfizer Investigational Site

    Rochester, New York

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma

  • Pfizer Investigational Site

    Beaver, Pennsylvania

  • Pfizer Investigational Site

    Doylestown, Pennsylvania

Showing 40 of 307 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.